Screener
ImmunityBio, Inc. IBRX Finance Lease Liabilities
Finance Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityNoncurrent.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Classification | March 31, 2026 | December 31, 2025 |
|---|---|---|---|
| Liabilities | |||
| Current: | |||
| Operating lease liabilities (including amounts with related parties) | Operating lease liabilities | $7,626 | $7,535 |
| Finance lease liabilities | Accrued expenses and other liabilities | 53 | 52 |
| Noncurrent: | |||
| Operating lease liabilities (including amounts with related parties) | Operating lease liabilities, less current portion | 33,147 | 33,447 |
| Finance lease liabilities | Other liabilities | 213 | 227 |
| Total lease liabilities (including amounts with related parties) | $41,039 | $41,261 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s finance lease liabilities?
- ImmunityBio, Inc. (IBRX) reported finance lease liabilities of $213K in Q1 2026.
- What does finance lease liabilities mean?
- Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.
Ask your AI about ImmunityBio, Inc.'s finance lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude